- The move follows international recognition of the treatment, which has received approvals from major regulatory bodies, including the US Food and Drug Administration (FDA), and has been adopted in several countries including Saudi Arabia, Canada, Switzerland, Australia, Japan and China.
- The treatment is intended for adults with type 1 and type 2 diabetes, subject to medical assessment and the applicable guidelines for its use once approved in Kuwait.
The Ministry of Health is expected to approve the use of a new weekly insulin treatment for diabetic patients in Kuwait, with the product’s registration file reportedly in the final stages of review and approval.
Once-weekly basal insulin treatments, such as Awiqli (insulin icodec), are advancing through global regulatory pipelines to reduce injection frequency from daily to weekly, supporting better management for adults with type 2 diabetes.
According to informed sources, the medication has not yet received official registration in Kuwait, but the approval process is expected to be completed soon. No specific date has been announced for its formal introduction.
The sources explained that the registration of new medicines involves detailed technical and regulatory assessments to verify safety, effectiveness and manufacturing standards before they are approved for use within the national healthcare system.
The move follows international recognition of the treatment, which has received approvals from major regulatory bodies, including the US Food and Drug Administration (FDA), and has been adopted in several countries including Saudi Arabia, Canada, Switzerland, Australia, Japan and China.
One Injection a Week Instead of Daily Doses
The new treatment, based on the active ingredient Insulin Icodec, is described as the world’s first weekly basal insulin designed to replace daily insulin injections for adults with diabetes.
Unlike traditional insulin regimens that require daily injections, the weekly formulation could reduce the number of injections from seven per week to just one, lowering the annual number of injections from around 365 to 52.
Health experts say reducing the frequency of injections could help improve treatment adherence among patients and ease the physical and psychological burden associated with daily insulin use.
The sources noted that fear of repeated injections remains one of the key reasons some patients delay starting insulin therapy, and the availability of a weekly option could encourage more consistent management of diabetes.
The treatment is intended for adults with type 1 and type 2 diabetes, subject to medical assessment and the applicable guidelines for its use once approved in Kuwait.
